Functional Fluidics was honored to participate in this event

organized by The New York Academy of Sciences in October of 2017:


Screenshot 2018-03-06 18.09.25.png

Overview

Every year, more than 300,000 people are born with sickle cell disease (SCD), a blood disorder marked by frequent vaso-occlusive crises (VOC) in which patients experience fatigue and extreme pain. These crises can lead to organ damage and in the long term, early mortality. To date, the FDA has only approved two treatments for the disease. But improved insight into the complex pathophysiology of SCD has led to the recent development of diverse approaches for treatment, including inhibition of hemoglobin polymerization, prevention and treatment of vaso-occlusive events, and disease corrective gene therapy approaches.

On October 24, 2017, the New York Academy of Sciences and the Biochemical Pharmacology Discussion Group presented Towards Transformative Therapies for Sickle Cell Disease. The event brought together leading researchers and scientists from across the field to discuss key biological mechanisms of the disease and innovative new approaches for treatment, while underscoring the importance of the patient experience.

New York Academy of Sciences members can download the event report by following this link

No other contract research company has more experience performing blood function assays to evaluate anti-adhesive therapies in Sickle Cell Disease than Functional Fluidics.

Overview

This short video describes the origins of the company, based on research in the Hines Lab at Wayne State University. We have developed a suite of assays that address the need for better ways to assess blood function, starting with the experience of Dr. Hines as a Pediatric ICU Physician at Detroit Medical Center.

Assays At A Glance

The following is a list of standardized assays that we offer. Please click on any description for more information.

Flow Adhesion

Blood samples (whole or isolated cellular components) at baseline or following drug treatment (single dose or dose response) are subjected to physiologic flow across an adhesive substrate of interest. Adhered cells are quantified to generate an adhesion index (AI).

Flow Thrombosis

Blood samples (whole or isolated platelets) are pre-treated with a drug of interest, and then subjected to physiologic arterial flow across a substrate of interest. A series of photomicrographs of fluorescently labeled blood (see Figure 3) is analyzed to determine the kinetics of thrombosis formation (lag time, max rate of thrombosis, area under the curve, and maximum amplitude).

Flow Adhesion Dynamic

Blood samples (whole or isolated cellular components) at baseline or following drug treatment (single dose or dose response) are subjected to physiologic flow across an adhesive substrate of interest (usually selectins). Time-lapse images are acquired to measure cell rolling / sliding along the channel surface. Mean velocity for rolling objects and cell flux is measured to generate a dynamic adhesion index (dAI).

Flow Adhesion Dynamic

Blood cells are adhered to a substrate of interest (see Flow Adhesion), followed by introduction of anti-adhesive drug under flow. Remaining adherent cells are measured to generate a reverse adhesion index (rAI).

Flow Adhesion Characterization

Adhered cells are fixed with 4% formalin and stained following an adhesion assay (FF-FA, FF-FAR, FF-FAA). Fluorescence microscopy is utilized to differentiate between and quantify specific cell populations.

Flow Adhesion Avidity

Blood cells are adhered to a substrate of interest (see Flow Adhesion), followed by introduction of sequentially increased shear. Remaining adherent cells are quantified followed by a sequential increase in shear (5, 10, and 20 dyne/cm^2), to generate an avidity adhesion index (aAI).

Gallery